FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063998062> ?p ?o ?g. }

• W2063998062 endingPage "1389" @default.
• W2063998062 startingPage "1387" @default.
• W2063998062 abstract "Clinically nonfunctioning pituitary adenomas (NFPAs) mostly arise from gonadotroph cells and account for about one-third of all pituitary tumors. Because they are not associated with hormone hypersecretion, these tumors are often diagnosed late when they are large and locally invasive. Consequently, the complete surgical removal of NFPAs is hard to achieve and they tend to recur. Medical treatment of NFPAs is still challenging because they are usually resistant to mainstay peptide receptor therapy with somatostatin (SRIF) analogs (octreotide and lanreotide) or dopamine agonists (bromocriptine and cabergoline). Indeed, although these agents may be useful in some cases to prevent residual tumor growth (1), their efficacy has not been confirmed in larger studies. Recently, SOM230 (pasireotide), a broad-range SRIF analog with affinity for SRIF receptor subtypes 1 to 3 and 5 (2) and BIM-23A760 (dopastatin), a chimeric agent interacting with both SRIF receptor and dopamine receptors were developed (3). However, NFPAs only partially respond to these compounds, at least in vitro (4, 5). After the discovery that NFPAs display overactivation of phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin pathway (6, 7), compounds inhibiting this signaling cascade at various levels have been tested against these tumors. The results are very promising, especially for dual inhibitors such as BEZ235 and XL765, which inhibit both mammalian target of rapamycin and the upstream phosphatidylinositol 3-kinase and exert a potent antiproliferative activity against primary human NFPA cells (8), rodent pituitary cell lines (9), and primary rat gonadotroph adenoma cells in vitro (10). In vivo studies are now required to prove or disprove the efficacy of these agents. Conventional chemotherapy has been one of the major medical advances of the last decades, but it is usually associated with poor specificity for the cancer cells and high toxicity to the normal cells. To overcome these limitations, it would be ideal to identify ways to deliver a biologically effective concentration of anticancer agents to the tumor tissues with very high specificity. To reach this ultimate goal, extensive efforts have been undertaken to develop tumor-selective drugs by conjugating therapeutic agents to hormones, antibodies, and vitamin derivatives. Among them, folic acid holds great promise as a tumor-homing agent (11). Folate (or folic acid) is an essential B vitamin, which plays a pivotal role in cell survival by participating in the biosynthesis of nucleic and amino acids. Folate is internalized into the cells via a low-affinity reduced folate carrier protein or via high-affinity folate receptors. The best studied isoform of these receptors is folate receptor(FR ), a cell surface glycosyl phosphatidylinositol-anchored glycoprotein that can internalize bound folates and folate-conjugated compounds via receptor-mediated endocytosis (12). Whereas FR has a very restricted expression pattern in normal tissues, it is expressed at a high level in various human cancers, particularly epithelial carcinomas, including nonmucinous ovarian carcinoma, cervical carcinomas, and testicular choriocarcinomas, and less frequently in breast, endometrial colon, and renal cell carcinomas (13, 14). Due to its selective expression in tumor but not normal cells, FR has become one of the most investigated cellular surface antigens for targeted delivery of a variety of molecules, including imaging agents, chemotherapeutic agents, oligodeoxynucleotides, and macromolecules. Various types of drug carriers have been conjugated to folate such as liposomes, lipid nanoparticles, polymeric nanoparticles, polymers, and micelles filled with the molecule that needs to be delivered (11). FR -targeted liposomal" @default.
• W2063998062 created "2016-06-24" @default.
• W2063998062 creator A5001450937 @default.
• W2063998062 creator A5047125112 @default.
• W2063998062 date "2013-04-01" @default.
• W2063998062 modified "2023-09-26" @default.
• W2063998062 title "Folate Receptor-Mediated Drug Targeting: A Possible Strategy for Nonfunctioning Pituitary Adenomas?" @default.
• W2063998062 cites W1980168230 @default.
• W2063998062 cites W1985359348 @default.
• W2063998062 cites W2005101034 @default.
• W2063998062 cites W2029042379 @default.
• W2063998062 cites W2057084566 @default.
• W2063998062 cites W2060882819 @default.
• W2063998062 cites W2062826804 @default.
• W2063998062 cites W2084329943 @default.
• W2063998062 cites W2097724606 @default.
• W2063998062 cites W2112295694 @default.
• W2063998062 cites W2117369752 @default.
• W2063998062 cites W2117868980 @default.
• W2063998062 cites W2131060408 @default.
• W2063998062 cites W2137953043 @default.
• W2063998062 cites W2150024614 @default.
• W2063998062 cites W2168906621 @default.
• W2063998062 cites W2170146827 @default.
• W2063998062 cites W4247050894 @default.
• W2063998062 doi "https://doi.org/10.1210/en.2013-1182" @default.
• W2063998062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23525581" @default.
• W2063998062 hasPublicationYear "2013" @default.
• W2063998062 type Work @default.
• W2063998062 sameAs 2063998062 @default.
• W2063998062 citedByCount "3" @default.
• W2063998062 countsByYear W20639980622021 @default.
• W2063998062 crossrefType "journal-article" @default.
• W2063998062 hasAuthorship W2063998062A5001450937 @default.
• W2063998062 hasAuthorship W2063998062A5047125112 @default.
• W2063998062 hasBestOaLocation W20639980621 @default.
• W2063998062 hasConcept C126322002 @default.
• W2063998062 hasConcept C134018914 @default.
• W2063998062 hasConcept C170493617 @default.
• W2063998062 hasConcept C2777428134 @default.
• W2063998062 hasConcept C2777658017 @default.
• W2063998062 hasConcept C2779318953 @default.
• W2063998062 hasConcept C2780035454 @default.
• W2063998062 hasConcept C71315377 @default.
• W2063998062 hasConcept C71924100 @default.
• W2063998062 hasConcept C98274493 @default.
• W2063998062 hasConceptScore W2063998062C126322002 @default.
• W2063998062 hasConceptScore W2063998062C134018914 @default.
• W2063998062 hasConceptScore W2063998062C170493617 @default.
• W2063998062 hasConceptScore W2063998062C2777428134 @default.
• W2063998062 hasConceptScore W2063998062C2777658017 @default.
• W2063998062 hasConceptScore W2063998062C2779318953 @default.
• W2063998062 hasConceptScore W2063998062C2780035454 @default.
• W2063998062 hasConceptScore W2063998062C71315377 @default.
• W2063998062 hasConceptScore W2063998062C71924100 @default.
• W2063998062 hasConceptScore W2063998062C98274493 @default.
• W2063998062 hasIssue "4" @default.
• W2063998062 hasLocation W20639980621 @default.
• W2063998062 hasLocation W20639980622 @default.
• W2063998062 hasOpenAccess W2063998062 @default.
• W2063998062 hasPrimaryLocation W20639980621 @default.
• W2063998062 hasRelatedWork W1967938070 @default.
• W2063998062 hasRelatedWork W1979660518 @default.
• W2063998062 hasRelatedWork W1996846474 @default.
• W2063998062 hasRelatedWork W2012488328 @default.
• W2063998062 hasRelatedWork W2033472167 @default.
• W2063998062 hasRelatedWork W2034583712 @default.
• W2063998062 hasRelatedWork W2047253938 @default.
• W2063998062 hasRelatedWork W2049972387 @default.
• W2063998062 hasRelatedWork W2074821979 @default.
• W2063998062 hasRelatedWork W2127836255 @default.
• W2063998062 hasVolume "154" @default.
• W2063998062 isParatext "false" @default.
• W2063998062 isRetracted "false" @default.
• W2063998062 magId "2063998062" @default.
• W2063998062 workType "article" @default.